Poster: In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in US hospitals - Infectious Disease Connect Poster: In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in US hospitals - Infectious Disease Connect

Academic Literature

Poster: In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in US hospitals

This poster was originally presented at European Congress of Clinical Microbiology and Infectious Diseases 2023, held April 15-18 in Copenhagen, Denmark.

Alina Iovleva, Christi L. McElheny, Erin L. Fowler, Carol Hill, Keri Baum, Vance G. Fowler, Jr., Henry F. Chambers, Kerryl E. Greenwood-Quaintance, Robin Patel, Robert A. Bonomo, David van Duin, Yohei Doi

Conclusions

  • Sulbactam-Durlobactam (SUL-DUR) is active against majority of colistin-resistant and cefiderocol-non-susceptible Carbapenem-resistant A. baumannii (CRAb)
  • Imipenem (IPM) further lowers MIC50 by 2- to 4-fold
  • Additional mechanisms of resistance are present as 5/10 SUL-DUR resistant isolates did not possess known mutations

Background

Materials and Methods

Results

Table 1. MIC50/90 for cefiderocol-non-susceptible isolates (n=26)
MIC (μg/mL)IPMSULSUL-DURIPM: SUL-DUR
Min4110.5
Max6464168
MIC50321641
MIC90646484
Table 2. MIC50/90 for colistin-resistant isolates (n=68)
MIC (μg/mL)IPMSULSUL-DURIPM: SUL-DUR
Min420.50.25
Max6464328
MIC5032821
MIC90643284
Figure 1. MICs of colistin-resistant (A) and cefiderocol-non-susceptible (B) isolates.

Funding

Funding: This study was supported by a grant from the National Institutes of Health to HFC and VGF (UM1AI104681), AI (KL2TR001856), and YD (R01AI104895). The authors thank Entasis for the provision of broth microdilution plates for the study.


You might also like…

ID Connect to Share Key Insights and Data at IDWeek 2024

Infectious Disease Connect and UNM SRMC Release Groundbreaking White Paper on Telemedicine’s Impact on Infectious Disease Care

ID Connect Named “Telehealth Company to Know” by Becker’s Hospital Review

Receive Your Copy of IDC’s Information

Please fill out the form below to access this content.

Thank you, the form submit was successful!